Genmab ups 2022 financial guidance

9 August 2022

Danish biotech Genmab (Nasdaq: GMAB) says it is improving its 2022 financial guidance that was published on May 11 this year.

The improved guidance is driven primarily by increased royalty revenue due to higher net sales of Darzalex (daratumumab) and the positive net foreign exchange impact of the strong US dollar.

Genmab expects its 2022 revenue to be in the range of 12,000 – 13,000 million Danish kroner ($1,639 million - $1,776 million), an increase to the previous guidance of 11,000 – 12,000 million kroner, driven primarily by the continued strong growth of Darzalex net sales as well as the positive impact of the strong US dollar. Genmab’s projected revenue for 2022 primarily consists of royalties from multiple myeloma drug Darzalex, which is marketed US healthcare giant Johnson & Jansson’s (NYSE: JNJ) subsidiary Janssen.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK